Sort by
Refine Your Search
-
Listed
-
Employer
-
Field
-
quantitative finance, particularly statistical arbitrage. What are you going to do? You will work 60% of the time on your PhD-project, and 40% of the time on projects at Deep Blue Capital. Those projects will be
-
, conservation biologists and demographers. Contribute to teaching 10% of the time, by supervising BSc and MSc students, and assisting on courses. Organisation Founded in 1614, the University of Groningen enjoys
-
on this project, and therefore, collaborative work between the two successful candidates is expected. The candidate is also expected to contribute to teaching for the MSc course in ornithology of the University
-
to contribute to teaching for the MSc course in ornithology of the University Gaston Berger, in Senegal, by dedicating up to 2-weeks per year of their time. In addition, the candidate is expected to offer MSc
-
on the following key questions: Analysing Centralization and Accessibility: Using population data from real world data sources such as cancer registries and data from the central bureau of statistics, the PhD
-
) assembly using colloidal systems as inspiration and with links to topic (1). The typical approach in the team is interdisciplinary, ranging from synthetic chemistry to statistical physics. The Feringa group
-
statistical skills (e.g., group and single case statistics, correlations). In accordance with the Collective Labour Agreement for Dutch Universities, the University of Groningen offers you: A salary of € 2.901
-
to develop language tests and assess language capacities in German. Medium to advanced statistical skills (e.g., group and single case statistics, correlations). Organisation Conditions of employment In
-
and/or Python. Experience in, and aptitude for, complex statistical modelling (inc. mixed effects regression models and/or Bayesian statistics). Excellent written and spoken English. Desirable (traits
-
treatment for cartilage defects combines autologous chondrons with allogeneic MSCs and is currently in phase III clinical trials. This project will build further on our expertise in this therapy and our